Mavyret

Active Ingredient(s): Glecaprevir + Pibrentasvir
FDA Approved: * August 3, 2017
Pharm Company: * ABBVIE INC
Category: Hepatitis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Mavyret Overview

Glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in Europe) is a combination drug containing glecaprevir (100mg) and pibrentasvir (40mg). In the United States, it was approved by the Food and Drug Administration in August 2017 for treatment of hepatitis C.[1] In Europe, it was also approved in August 2017 for the same indication.[2] Contents 1 Medical uses 2 Side effects 3 Clinical trials 4 Development 5 References Medical uses Mavyret is the brand name a combina...

Read more Mavyret Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Glecaprevir/pibrentasvir

Recent Mavyret Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Glecaprevir + Pibrentasvir
  • Tablet: 100mg + 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Mavyret: (1 result)

Sorted by National Drug Code
  • 0074-2625 Mavyret Oral Tablet, Film Coated by Abbvie Inc.

Drugs with one or more similar ingredients: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2018 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 23 May 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.